Population pharmacokinetic modeling of caffeine in preterm infants with apnea of prematurity: New findings from concomitant erythromycin and AHR genetic polymorphisms

• Published in: Pharmacological research 2022-10, Vol.184, p.106416-106416, Article 106416
• Main Authors: Dai, Hao-Ran, Liu, Yun, Lu, Ke-Yu, He, Xin, Guo, Hong-Li, Hu, Ya-Hui, Xu, Jing, Ding, Xuan-Sheng, Chen, Feng, Cheng, Rui, Jiao, Zheng
• Format: Article
• Language: English
• Subjects: Apnea of prematurity; Aryl hydrocarbon receptor; Caffeine; Erythromycin; Population pharmacokinetics; Preterm infants
• ISSN: 1043-6618; 1096-1186
• DOI: 10.1016/j.phrs.2022.106416

Current standard-dose caffeine therapy results in significant intersubject variability. The aims of this study were to develop and evaluate population pharmacokinetic (PPK) models of caffeine in preterm infants through comprehensive screening of covariates and then to propose model-informed precision dosing of caffeine for this population. A total of 129 caffeine concentrations from 96 premature neonates were incorporated into this study. Comprehensive medical record and genotype data of these neonates were collected for analysis. PPK modeling was performed by a nonlinear mixed effects modeling program (NONMEM). Final models based on the current weight (CW) or body surface area (BSA) were evaluated via multiple graphic and statistical methods. The model-informed dosing regimen was performed through Monte Carlo simulations. In addition to CW or BSA, postnatal age, coadministration with erythromycin (ERY), and aryl hydrocarbon receptor coding gene (AHR) variant (rs2158041) were incorporated into the final PPK models. Multiple evaluation results showed satisfactory prediction performance and stability of the CW- and BSA-based models. Monte Carlo simulations demonstrated that trough concentrations of caffeine in preterm infants would be affected by concomitant ERY therapy and rs2158041 under varying dose regimens. For the first time, ERY and rs2158041 were found to be associated with the clearance of caffeine in premature infants. Similar predictive performance and stability were obtained for both CW- and BSA-based PPK models. These findings provide novel insights into caffeine precision therapy for preterm infants. [Display omitted]